JOHNSON & JOHNSON JNJ

Healthcare

Johnson & Johnson, through its subsidiaries, is engaged in the research and development, manufacture, and sale of a range of products in the healthcare field. The Company's primary focus is products related to human health and well-being. It operates through two segments: Innovative Medicine and MedTech. The Innovative Medicine segment is focused on various therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, pulmonary hypertension, and cardiovascular and metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the orthopedic, surgery, interventional solutions, cardiovascular intervention, and vision fields. The MedTech segment also offers a commercially available intravascular lithotripsy (IVL) platform for coronary artery disease (CAD) and peripheral artery disease (PAD).

NYSE:JNJ - Post by User

JOHNSON & JOHNSON

Bullboard Posts

Comment by mhoganon Feb 14, 2000 6:00pm

138 Views

Post# 1372137

RE: JNJ on CNBC today

After hours on Friday, JNJ announced it completed its $85 mln merger with Innovasive Devices (IDEA), a manufacturer of surgical devices and instrumentation. Innovasive shareholders approved the deal and will receive 0.948 shares of JNJ common stock for every share of Innovasive stock they own. JNJ also reported that over the next 90 days it will buy back the number of shares used in the merger.

Bullboard Posts

Three micro-cap value stocks trading at peak pessimism